[Cited FineTest ELISA Kit] Current Research on Colorectal Cancer Biomarker

FineTest ELISA kit contributes to the research on colorectal cancer biomarker. The immunoassay is designed to measure EIF3B level in plasma.

Article Title: Integrative proteomic profiling of tumor and plasma extracellular vesicles identifies a diagnostic biomarker panel for colorectal cancer
Journal Title: Cell Reports Medicine
DOI: 10.1016/j.xcrm.2025.102090
IF: 11.7
PMID: 40311616

Abstract: The lack of reliable non-invasive biomarkers for early colorectal cancer (CRC) diagnosis underscores the need for improved diagnostic tools. Extracellular vesicles (EVs) have emerged as promising candidates for liquid-biopsy-based cancer monitoring. Here, we propose a comprehensive workflow that integrates staged mass spectrometry (MS)-based discovery and verification with ELISA-based validation to identify EV protein biomarkers for CRC. Our approach, applied to 1,272 individuals, yields a machine learning model, ColonTrack, incorporating EV proteins HNRNPK, CTTN, and PSMC6. ColonTrack effectively distinguishes CRC from non-CRC cases and identifies early-stage CRC with high accuracy (combined area under the curve [AUC] >0.97, sensitivity ∼0.94, specificity ∼0.93). Our analysis of EV protein profiles from tissue and plasma demonstrates ColonTrack’s potential as a robust non-invasive biomarker panel for CRC diagnosis and early detection.

Keywords: Tissue Extracellular Vesicles, Diagnostic Biomarker Panel, Early Diagnosis of Colorectal Cancer, Proteomics

Immunoassay

Validated Image

Figure Source: Cell Rep Med. 2025 May 20;6(5):102090. doi: 10.1016/j.xcrm.2025.102090.